Quick Answer
RenovoRx, Inc. reported Diluted EPS of $0.32 per share (loss) for fiscal year 2025.
RenovoRx, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.32 | +20.0% |
| 2024 | -$0.40 | +59.6% |
| 2023 | -$0.99 | +9.2% |
| 2022 | -$1.09 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.08 | +20.0% | +0.0% |
| June 30, 2025 | -$0.08 | +20.0% | +0.0% |
| March 31, 2025 | -$0.08 | -14.3% | +20.0% |
| September 30, 2024 | -$0.10 | +23.1% | +0.0% |
| June 30, 2024 | -$0.10 | +54.5% | -42.9% |
| March 31, 2024 | -$0.07 | +80.6% | +46.2% |
| September 30, 2023 | -$0.13 | +45.8% | +40.9% |
| June 30, 2023 | -$0.22 | +24.1% | +38.9% |
- RenovoRx, Inc. showed an increase of +20.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, RenovoRx, Inc.’s diluted eps has grown by 70.6% (from $1.09 per share (loss) to $0.32 per share (loss)).
- The most recent figure is from RenovoRx, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: